Caption Management, LLC Arcus Biosciences, Inc. Put Options Transaction History

Caption Management, LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$13.69 - $18.01 $410,700 - $540,300	-30,000 Reduced 50.0%	30,000 $458,000
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $875,400 - $1.11 Million	60,000 New	60,000 $913,000
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $671,500 - $981,500	50,000 New	50,000 $955,000
Q2 2023 Aug 14, 2023	SELL	$16.97 - $22.03 $848,500 - $1.1 Million	-50,000 Reduced 62.5%	30,000 $609,000
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $1.28 Million - $1.85 Million	80,000 New	80,000 $1.46 Million
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $6.18 Million - $13.5 Million	358,900 Added 1595.11%	381,400 $9.67 Million
Q1 2022 May 13, 2022	BUY	$28.92 - $41.83 $650,700 - $941,175	22,500 New	22,500 $710,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.08B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.